Abstract
The steroid SC17599 (17α-acetoxy-6-dimethylaminomethyl-21-fluoro-3-ethoxypregna-3,5-dien-20-one) has μ-opioid actions in vivo. The ability of SC17599 to interact with opioid receptors has been studied using radioligand and [35S]guanosine-5′-O-(3-thio)triphosphate (GTPγS) binding assays. SC17599 bound to μ-opioid receptors in SH-SY5Y neuroblastoma cells and to recombinant receptors expressed in rat C6 glioma cells and Chinese hamster ovary cells with good affinity and with greater than 100-fold selectivity for μ- over both δ- and κ-opioid receptors. Binding was much reduced when aspartate 147 in the wild-type μ-opioid receptor was replaced with asparagine. The affinity of SC17599 for the μ-opioid receptor was decreased in the presence of sodium ions, indicating agonist activity. SC17599 stimulated the binding of [35S]GTPγS in a naloxone-reversible manner with good potency and maximal effect equivalent to that of the μ-opioid agonists fentanyl and [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin. In rat brain membranes, SC17599-mediated stimulation of [35S]GTPγS binding was reversed by the antagonist naltrexone. SC17599 lacks an aromatic ring andpara-hydroxyl substituent considered critical in the pharmacophore for μ-opioids. The structural relationship between SC17599 and more traditional opioid ligands was investigated through genetic algorithm-based modeling techniques for pharmacophore generation (GASP) and ligand-receptor docking (GOLD). The relatively planar and electron-rich A ring of the steroid compensated for the lack of aromaticity. Modeling of ligand-receptor docking showed that both morphine and SC17599 occupy the same binding pocket within the transmembrane helix bundle of the μ-opioid receptor and that the relationship between their binding modes largely mimicked the pharmacophore alignment.
Footnotes
- Received November 3, 1999.
- Accepted July 27, 2000.
-
Send reprint requests to: Dr. J. R. Traynor, Department of Pharmacology, University of Michigan, 1301 MSRB III, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0632. E-mail:jtraynor{at}umich.edu
-
This work was supported by National Institute of Health Grants DA03910 and DA00254. We also thank the EPSRC (UK) for the studentship award to I.J.M.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|